ASH 2023 | Novel agents to improve outcomes for patients with multiple myeloma in the salvage setting
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses advances in the myeloma treatment landscape which he hopes will improve outcomes for patients who are refractory to first-line triple-class treatment. Agents targeting BCMA, GPRC5D, and FcRH5, whether used alone or in combination with standard-of-care (SoC) regimens, have the potential to enhance outcomes and personalize treatment. Incorporating these agents in earlier treatment settings is recommended. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
In multiple myeloma, we clearly are getting patients who are treated with the triple main classes of drugs in the newly diagnosed setting, and patients can become refractory to these therapies within 2 to 3 years from diagnosis. Often these patients were not salvageable, but we now have BCMA-targeted, GPRC5D-targeted, and soon FCRH5-targeted medications.
A lot of these medications are now available in routine clinical practice, and they’re now also being combined with other standard-of-care agents to improve outcomes...
In multiple myeloma, we clearly are getting patients who are treated with the triple main classes of drugs in the newly diagnosed setting, and patients can become refractory to these therapies within 2 to 3 years from diagnosis. Often these patients were not salvageable, but we now have BCMA-targeted, GPRC5D-targeted, and soon FCRH5-targeted medications.
A lot of these medications are now available in routine clinical practice, and they’re now also being combined with other standard-of-care agents to improve outcomes. And this is what excites me, because this provides greater opportunity for us to treat patients, potentially personalized care for patients, which will improve survival. But we should continue to strive to diagnose patients early and treat patients early, and put them in deep remissions for longer periods of time. And hopefully, with all these new drug assets we have, we can start to shift them more to earlier treatment setting and improve outcomes for patients.
Read more...
Disclosures
Sanofi: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Adaptive Biotech: Honoraria, Membership on an entity’s Board of Directors or advisory committees; GSK: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Menarini Stemline: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Recordati: Honoraria; BMS ( Celgene): Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding.
